x

Coronavirus

Australia Okays Pfizer Vaccine, Inoculations to Begin in February

SYDNEY — Australia’s medical regulator has approved use of its first coronavirus vaccine, paving the way for inoculations to begin next month.

The Therapeutic Goods Administration on Monday gave provisional approval for people aged 16 and over to use the vaccine developed by Pfizer and BioNTech. Residents and workers at aged-care facilities, frontline healthcare workers and quarantine workers are among the groups being prioritized for the first doses.

Australian Prime Minister Scott Morrison welcomed the development. He said Australia was among the first countries to complete a comprehensive process to formally approve a vaccine rather than just grant an emergency approval.

Australia has an agreement for 10 million doses of the two-dose Pfizer vaccine and an option to buy more if supplies allow. It also has ordered, conditional on regulatory approval, 53.8 million doses of the vaccine made by AstraZeneca and Oxford University, 50 million of which would be made in Australia in a partnership with Melbourne-based biopharmaceutical company CSL.

Australia is aiming to complete inoculations by October. The nation of 26 million people has reported fewer than 30,000 virus cases and a little over 900 deaths.

RELATED

NEW YORK — New York City, which once had the nation’s strictest workplace vaccination rules for COVID-19, is ending one of its last such mandates, saying it will no longer require the shots for municipal employees including police officers, firefighters and teachers.

Top Stories

Columnists

A pregnant woman was driving in the HOV lane near Dallas.

General News

FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.

General News

NEW YORK – Meropi Kyriacou, the new Principal of The Cathedral School in Manhattan, was honored as The National Herald’s Educator of the Year.

Video

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. [email protected]

You may unsubscribe at any time using the link in our newsletter.